Tasquinimod: Additional Phase II data
Additional data from a double-blind, international Phase II trial in 206 asymptomatic, metastatic CRPC patients showed that low levels of transforming growth factor (TGF) beta 1 (TGFB1) (p=0.029), thrombospondin-1 ( TSP-1; THBS1) (p=0.017) and VEGF-C (p=0.034) at week 8 were correlated with longer survival in patients receiving tasquinimod vs. placebo. Data were presented at the European Society for Medical Oncology meeting in Vienna.
Active Biotech previously reported that tasquinimod met the primary endpoint of a smaller rate of disease progression at 6 months vs. placebo (37% vs. 69%, p<0.0001), as well as the secondary endpoint of median PFS (7.6 vs. 3.3 months, p=0.0042) (see BioCentury, Dec, 21, 2009 & June 21, 2010). Earlier this year, Active Biotech reported that tasquinimod led to median overall survival (OS) of 34.2 months vs. 30.2 months for placebo. However, the Phase II trial was not powered to detect an improvement in OS (see BioCentury, May 21). ...